Acute cellular and antibody-mediated rejection of the pancreas allograft: Incidence, risk factors and outcomes

S. V. Niederhaus, G. E. Leverson, D. F. Lorentzen, D. J. Robillard, H. W. Sollinger, J. D. Pirsch, J. R. Torrealba, J. S. Odorico

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Antibody-mediated rejection (AMR) after pancreas transplantation is a recently identified entity. We describe the incidence of, risk factors for, and outcomes after AMR, and the correlation of C4d immunostaining and donor-specific antibody (DSA) in the diagnosis of AMR. We retrospectively analyzed 162 pancreas transplants in 159 patients who underwent 94 pancreas allograft biopsies between 2006 and 2009. Univariate and multivariate analyses were performed to evaluate risk factors for pancreas graft AMR. One-year rejection rates and survival after rejection were calculated by Kaplan-Meier methods. AMR occurred in 10% of patients by 1-year posttransplant. Multivariate risk factors identified for AMR include nonprimary simultaneous pancreas-kidney (SPK) transplant, primary solitary pancreas (PAN) transplant and race mismatch. After pancreas rejection, patient survival was 100% but 20% (8 of 41) of pancreas grafts failed within 1 year. Graft survival after acute cellular rejection (ACR), AMR and mixed rejection was similar. Of biopsies that stained >5% C4d, 80% were associated with increased Class I DSA. In summary, AMR occurs at a measurable rate after pancreas transplantation, and the diagnosis should be actively sought using C4d staining and DSA levels in patients with graft dysfunction, especially after nonprimary SPK and primary PAN transplantation.

Original languageEnglish (US)
Pages (from-to)2945-2955
Number of pages11
JournalAmerican Journal of Transplantation
Volume13
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Allografts
Pancreas
Antibodies
Incidence
Transplants
Pancreas Transplantation
Tissue Donors
Kidney
Biopsy
Graft Survival
Multivariate Analysis
Survival Rate
Staining and Labeling
Survival

Keywords

  • Antibody-mediated rejection
  • biopsy
  • cellular rejection
  • donor-specific antibody
  • kidney transplantation
  • outcomes
  • pancreas transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Niederhaus, S. V., Leverson, G. E., Lorentzen, D. F., Robillard, D. J., Sollinger, H. W., Pirsch, J. D., ... Odorico, J. S. (2013). Acute cellular and antibody-mediated rejection of the pancreas allograft: Incidence, risk factors and outcomes. American Journal of Transplantation, 13(11), 2945-2955. https://doi.org/10.1111/ajt.12443

Acute cellular and antibody-mediated rejection of the pancreas allograft : Incidence, risk factors and outcomes. / Niederhaus, S. V.; Leverson, G. E.; Lorentzen, D. F.; Robillard, D. J.; Sollinger, H. W.; Pirsch, J. D.; Torrealba, J. R.; Odorico, J. S.

In: American Journal of Transplantation, Vol. 13, No. 11, 11.2013, p. 2945-2955.

Research output: Contribution to journalArticle

Niederhaus, SV, Leverson, GE, Lorentzen, DF, Robillard, DJ, Sollinger, HW, Pirsch, JD, Torrealba, JR & Odorico, JS 2013, 'Acute cellular and antibody-mediated rejection of the pancreas allograft: Incidence, risk factors and outcomes', American Journal of Transplantation, vol. 13, no. 11, pp. 2945-2955. https://doi.org/10.1111/ajt.12443
Niederhaus, S. V. ; Leverson, G. E. ; Lorentzen, D. F. ; Robillard, D. J. ; Sollinger, H. W. ; Pirsch, J. D. ; Torrealba, J. R. ; Odorico, J. S. / Acute cellular and antibody-mediated rejection of the pancreas allograft : Incidence, risk factors and outcomes. In: American Journal of Transplantation. 2013 ; Vol. 13, No. 11. pp. 2945-2955.
@article{d842f21406724fd1ac826f33b067cbf5,
title = "Acute cellular and antibody-mediated rejection of the pancreas allograft: Incidence, risk factors and outcomes",
abstract = "Antibody-mediated rejection (AMR) after pancreas transplantation is a recently identified entity. We describe the incidence of, risk factors for, and outcomes after AMR, and the correlation of C4d immunostaining and donor-specific antibody (DSA) in the diagnosis of AMR. We retrospectively analyzed 162 pancreas transplants in 159 patients who underwent 94 pancreas allograft biopsies between 2006 and 2009. Univariate and multivariate analyses were performed to evaluate risk factors for pancreas graft AMR. One-year rejection rates and survival after rejection were calculated by Kaplan-Meier methods. AMR occurred in 10{\%} of patients by 1-year posttransplant. Multivariate risk factors identified for AMR include nonprimary simultaneous pancreas-kidney (SPK) transplant, primary solitary pancreas (PAN) transplant and race mismatch. After pancreas rejection, patient survival was 100{\%} but 20{\%} (8 of 41) of pancreas grafts failed within 1 year. Graft survival after acute cellular rejection (ACR), AMR and mixed rejection was similar. Of biopsies that stained >5{\%} C4d, 80{\%} were associated with increased Class I DSA. In summary, AMR occurs at a measurable rate after pancreas transplantation, and the diagnosis should be actively sought using C4d staining and DSA levels in patients with graft dysfunction, especially after nonprimary SPK and primary PAN transplantation.",
keywords = "Antibody-mediated rejection, biopsy, cellular rejection, donor-specific antibody, kidney transplantation, outcomes, pancreas transplantation",
author = "Niederhaus, {S. V.} and Leverson, {G. E.} and Lorentzen, {D. F.} and Robillard, {D. J.} and Sollinger, {H. W.} and Pirsch, {J. D.} and Torrealba, {J. R.} and Odorico, {J. S.}",
year = "2013",
month = "11",
doi = "10.1111/ajt.12443",
language = "English (US)",
volume = "13",
pages = "2945--2955",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Acute cellular and antibody-mediated rejection of the pancreas allograft

T2 - Incidence, risk factors and outcomes

AU - Niederhaus, S. V.

AU - Leverson, G. E.

AU - Lorentzen, D. F.

AU - Robillard, D. J.

AU - Sollinger, H. W.

AU - Pirsch, J. D.

AU - Torrealba, J. R.

AU - Odorico, J. S.

PY - 2013/11

Y1 - 2013/11

N2 - Antibody-mediated rejection (AMR) after pancreas transplantation is a recently identified entity. We describe the incidence of, risk factors for, and outcomes after AMR, and the correlation of C4d immunostaining and donor-specific antibody (DSA) in the diagnosis of AMR. We retrospectively analyzed 162 pancreas transplants in 159 patients who underwent 94 pancreas allograft biopsies between 2006 and 2009. Univariate and multivariate analyses were performed to evaluate risk factors for pancreas graft AMR. One-year rejection rates and survival after rejection were calculated by Kaplan-Meier methods. AMR occurred in 10% of patients by 1-year posttransplant. Multivariate risk factors identified for AMR include nonprimary simultaneous pancreas-kidney (SPK) transplant, primary solitary pancreas (PAN) transplant and race mismatch. After pancreas rejection, patient survival was 100% but 20% (8 of 41) of pancreas grafts failed within 1 year. Graft survival after acute cellular rejection (ACR), AMR and mixed rejection was similar. Of biopsies that stained >5% C4d, 80% were associated with increased Class I DSA. In summary, AMR occurs at a measurable rate after pancreas transplantation, and the diagnosis should be actively sought using C4d staining and DSA levels in patients with graft dysfunction, especially after nonprimary SPK and primary PAN transplantation.

AB - Antibody-mediated rejection (AMR) after pancreas transplantation is a recently identified entity. We describe the incidence of, risk factors for, and outcomes after AMR, and the correlation of C4d immunostaining and donor-specific antibody (DSA) in the diagnosis of AMR. We retrospectively analyzed 162 pancreas transplants in 159 patients who underwent 94 pancreas allograft biopsies between 2006 and 2009. Univariate and multivariate analyses were performed to evaluate risk factors for pancreas graft AMR. One-year rejection rates and survival after rejection were calculated by Kaplan-Meier methods. AMR occurred in 10% of patients by 1-year posttransplant. Multivariate risk factors identified for AMR include nonprimary simultaneous pancreas-kidney (SPK) transplant, primary solitary pancreas (PAN) transplant and race mismatch. After pancreas rejection, patient survival was 100% but 20% (8 of 41) of pancreas grafts failed within 1 year. Graft survival after acute cellular rejection (ACR), AMR and mixed rejection was similar. Of biopsies that stained >5% C4d, 80% were associated with increased Class I DSA. In summary, AMR occurs at a measurable rate after pancreas transplantation, and the diagnosis should be actively sought using C4d staining and DSA levels in patients with graft dysfunction, especially after nonprimary SPK and primary PAN transplantation.

KW - Antibody-mediated rejection

KW - biopsy

KW - cellular rejection

KW - donor-specific antibody

KW - kidney transplantation

KW - outcomes

KW - pancreas transplantation

UR - http://www.scopus.com/inward/record.url?scp=84886797580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886797580&partnerID=8YFLogxK

U2 - 10.1111/ajt.12443

DO - 10.1111/ajt.12443

M3 - Article

C2 - 24102905

AN - SCOPUS:84886797580

VL - 13

SP - 2945

EP - 2955

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 11

ER -